Sleeping Beauty Transposase Antibody

• Reactivity: All-Multi
• Applications: WB, IHC
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

Sleeping Beauty Transposase Antibody Summary

• Immunogen: E. coli-derived recombinant Sleeping Beauty Transposase
• Specificity: Detects Sleeping Beauty Transposase in direct ELISAs and Western blots.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 5-15 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Sleeping Beauty Transposase Antibody

• SB Transposase

Background

SB transposase is the catalytic component of a DNA transposition system that catalyzes the excision of the transposon from its original location and promotes its reintegration elsewhere in the genome. An active transposase that acts on transposon sequences found in vertebrate genomes was reconstructed from consensus sequences of several mutated and inactive Tc1/mariner family transposase genes in salmonid fish. The entire 340 amino aa transposase sequence contains a paired‑like domain with a leucine zipper for DNA binding, a nuclear localization sequence (NLS), a glycine-rich box and a DD(34)E box. The recognition domain for transposon DNA is contained within the first 123 aa of the transposase (1).

1. Ivics, Z. et al. (1997) Cell 91:501.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Sleeping Beauty Transposase Antibody (AF2798)(10)

Publications using AF2798

• Dacheux, MA;Wu, MJ;Scherzer, MT;Nillson, M;Murphy, B;Schuman, S;Ju, Z;Bivona, T;Lito, P;Gumbleton, M;Puri, S;Akerley, W;Wang, J;Wang, K;Heymach, J;Kinsey, CG;Negrao, M;McMahon, M;Vaishnavi, A; BRAFV600E-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling bioRxiv : the preprint server for biology 2025-05-09 [PMID: 40654950] (Immunohistochemistry, Mouse)
• Aria Vaishnavi, Joseph Juan, Maebh Jacob, Christopher Stehn, Eric E. Gardner, Michael T. Scherzer et al. Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis Cancer Research 2022-11-15 [PMID: 36112789] (Immunohistochemistry, Transgenic Mouse)
• C Miskey, L Kesselring, I Querques, G Abrusán, O Barabas, Z Ivics Engineered Sleeping Beauty transposase redirects transposon integration away from genes Nucleic Acids Research, 2022-03-21;0(0):. 2022-03-21 [PMID: 35188569] (Western Blot, Human)
• MC Rotiroti, C Buracchi, S Arcangeli, S Galimberti, MG Valsecchi, VM Perriello, T Rasko, G Alberti, CF Magnani, C Cappuzzell, F Lundberg, A Pande, G Dastoli, M Introna, M Serafini, E Biagi, Z Izsvák, A Biondi, S Tettamanti Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System Mol. Ther., 2020-05-30;0(0):. 2020-05-30 [PMID: 32526203] (Western Blot, Human)
• Regulated complex assembly safeguards the fidelity of Sleeping Beauty transposition Nucleic Acids Res, 2016-12-01;0(0):. 2016-12-01 [PMID: 27913727] (Western Blot, Human)
• Transposon mutagenesis identifies genes that cooperate with mutant Pten in breast cancer progression Proc. Natl. Acad. Sci. U.S.A., 2016-11-14;0(0):. 2016-11-14 [PMID: 27849608] (IHC-P, Mouse)
• F Voigt, L Wiedemann, C Zuliani, I Querques, A Sebe, L Mátés, Z Izsvák, Z Ivics, O Barabas Sleeping Beauty transposase structure allows rational design of hyperactive variants for genetic engineering Nat Commun, 2016-03-30;7(0):11126. 2016-03-30 [PMID: 27025571] (IHC, Western Blot, Human)
• Mann M, Black M, Jones D, Ward J, Yew C, Newberg J, Dupuy A, Rust A, Bosenberg M, McMahon M, Print C, Copeland N, Jenkins N Transposon mutagenesis identifies genetic drivers of Braf(V600E) melanoma. Nat Genet, 2015-04-13;47(5):486-95. 2015-04-13 [PMID: 25848750] (IHC-P, Mouse)
• Quintana R, Dupuy A, Bravo A, Casanova M, Alameda J, Page A, Sanchez-Viera M, Ramirez A, Navarro M A transposon-based analysis of gene mutations related to skin cancer development. J Invest Dermatol, 2012-07-26;133(1):239-48. 2012-07-26 [PMID: 22832494] (IHC-P, Western Blot, Mouse)
• Collier LS, Adams DJ, Hackett CS, Bendzick LE, Akagi K, Davies MN, Diers MD, Rodriguez FJ, Bender AM, Tieu C, Matise I, Dupuy AJ, Copeland NG, Jenkins NA, Hodgson JG, Weiss WA, Jenkins RB, Largaespada DA Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality. Cancer Res., 2009-10-20;69(21):8429-37. 2009-10-20 [PMID: 19843846] (IHC-P, Mouse)